{Reference Type}: Journal Article
{Title}: Genetic Variations Affect Chemotherapy Outcomes: A Role of the Spindle-assembly Checkpoint.
{Author}: Sarkar S;Pal R;Choudhury T;Vernekar M;Nath P;Nasare VD;
{Journal}: Indian J Public Health
{Volume}: 68
{Issue}: 2
{Year}: 2024 Apr 1
{Factor}: 2.219
{DOI}: 10.4103/ijph.ijph_809_23
{Abstract}: Cancer patients suffer from complicated chemotoxicity. Pharmacogenomics can help stratify patients by predicting their response to treatment and susceptibility toward severe side effects. The spindle-assembly checkpoint (SAC) is an important pathway that is activated by platinum and taxane compounds and plays a crucial role in their cytotoxic activity. This study investigated a SAC component, Budding Uninhibited by Benzimidazoles 3 (BUB3), its expression, and genetic variants in advanced ovarian cancer patients treated with paclitaxel-carboplatin chemotherapy. Among 80 patients, BUB3 expression correlated with chemosensitivity, suggesting its potential as a predictive marker for chemotherapy response. However, high BUB3 expression was associated with a higher risk of poor survival. In addition, genetic polymorphisms in BUB3 (rs11248416 and rs11248419) were significantly linked to chemotherapy-related toxicities, with rs11248416 showing a negative impact on the patient's physical quality of life.